Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

Abstract Introduction Ciltacabtagene autoleucel (cilta‐cel) is a novel chimeric antigen receptor T‐cell therapy that is being evaluated in the CARTITUDE‐1 trial (NCT03548207) in patients with relapsed or refractory multiple myeloma (RRMM) who received as part of their previous therapy an immunomodul...

Full description

Bibliographic Details
Main Authors: Thomas Martin, Amrita Krishnan, Kwee Yong, Katja Weisel, Maneesha Mehra, Sandhya Nair, Keqin Qi, Anil Londhe, Joris Diels, Concetta Crivera, Carolyn C. Jackson, Yunsi Olyslager, Martin Vogel, Jordan M. Schecter, Arnob Banerjee, Satish Valluri, Saad Z. Usmani, Jesus G. Berdeja, Sundar Jagannath
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:eJHaem
Subjects:
CARTITUDE‐1
ciltacabtagene autoleucel
Flatiron Health
indirect treatment comparison
relapsed or refractory multiple myeloma
triple‐class exposed
Online Access:https://doi.org/10.1002/jha2.312

Internet

https://doi.org/10.1002/jha2.312

Similar Items